Stocks / ABT
ABT stock forecast
ABBOTT LABORATORIES · Healthcare · Medical Devices
Where this rating comes from: The Upfront Model, whose picks have been recorded with a fingerprint the day they publish since September 18, 2026. See the record.
ABT is not among the 20 largest holdings published for 2026 Q4. See the portfolio
ABT against the S&P 500
| Period | ABT | S&P 500 (SPY) |
|---|---|---|
| 1 month | +0.4% | -4.7% |
| 3 months | -8.1% | -4.8% |
| Year to date | -14.6% | +7.9% |
| 1 year | -17.7% | +11.8% |
Total return, dividends included.
Key numbers
| Price | $104.48 |
| Market cap | 180.95 Billion |
| P/E (trailing 12 months) | 38.8 |
| P/S (trailing 12 months) | 3.8 |
| P/B (latest quarter) | 3.9 |
| Gross margin | 56.9% |
| Net profit margin | 9.7% |
| Return on equity | 9.0% |
| Beta | 0.1 |
As of November 4, 2026.
ABT and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| MDT | MEDTRONIC PLC | 128.83 Billion | Outperform | ABT vs MDT |
| SYK | STRYKER CORP | 121.12 Billion | Greatly Underperform | ABT vs SYK |
| BSX | BOSTON SCIENTIFIC CORP | 63.26 Billion | Greatly Outperform | ABT vs BSX |
| EW | EDWARDS LIFESCIENCES CORP | 60.51 Billion | Underperform | |
| DXCM | DEXCOM INC | 30.78 Billion | Outperform | |
| STE | STERIS PLC | 25.21 Billion | Greatly Underperform |
Questions
What does the Upfront Investment model say about ABT?
The model rates ABBOTT LABORATORIES (ABT) "Underperform" as of November 18, 2026, which means its medium-term return forecast is below the middle of the stocks the model scores, but above the bottom fifth. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the ABT rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is ABT in the Upfront Investment model portfolio?
ABT is not among the 20 largest holdings published for 2026 Q4.
The rating is generated by The Upfront Model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.